Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — 29th Annual ROTH Conference 2017

28 slides from Sorrento Therapeutics's conference presentation, Mar 13, 2017

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    Corporate Presentation 29th Annual ROTH Conference March 13, 2017

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward-looking statements” as defined in th

  3. Slide 3: Sorrento Therapeutics Corporate History

    Slide 3: Sorrento Therapeutics Corporate History

    Sorrento Therapeutics Corporate History October 2013: Acquired December 2014: JV to March 2016: JV to November 2016: Announced Sherrington Pharmaceuticals develop next-gen CAR- develop checkpoint proposed acquisition of VIRTTU and its drug candidate RTX NK therapy for cancer inhibitors ($10mm from B

  4. Slide 4: Sorrento Overview

    Slide 4: Sorrento Overview

    Sorrento Overview › Novel technology platforms and development programs focused on antibody therapy, cell-based immunotherapy and pain management Partners Subs/JVs › Antibody Therapy (G-MAB™, LA Cell, Concortis, Sorrento Biologics): mAbs for highly coveted IO targets, next-gen intracellular targetin

  5. Slide 5: Corporate Structure

    Slide 5: Corporate Structure

    Corporate Structure © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 5

  6. Slide 6: Overview of Sorrento Therapeutics

    Slide 6: Overview of Sorrento Therapeutics

    Overview of Sorrento Therapeutics Antibody Therapy Cell-Based Immunotherapy Pain Management G-MAB & Sorrento Scilex Scintilla Concortis™ TNK Therapeutics™ VIRTTU Biologics™ LA Cell Biologics™ Pharmaceuticals™ Pharmaceuticals™ Key Technology Platforms Key Technology Platforms Key Technology Platforms

  7. Slide 7: Antibody Therapy Business: G-MAB Fully Human Antibody Library

    Slide 7: Antibody Therapy Business: G-MAB Fully Human Antibody Library

    Sorrento Antibody Therapy Business: G-MAB Fully Human Antibody Library Difficult Targets High Value Oncology Targets G Protein-Coupled Receptors Small Peptides & Tumor Neo-epitopes PD1, PD-L1, CD123, CD38, CD47 (GPCRs) F L S Y G N A G AIP-2 One of the Largest Fully Human Highly Successful Screening

  8. Slide 8: Evolution of Antibody Therapy

    Slide 8: Evolution of Antibody Therapy

    Evolution of Antibody Therapy 2nd Gen Antibodies 3rd Gen Antibodies 1st Gen Antibodies iTAb: Next Wave in Antibody Chimeric, Humanized, ADCs, Bispecifics, Fc-engineering, Murine mAbs Therapy Intracellular Targeting mAbs Fully Human mAbs Antibody Fragments Sold for $2.2bn $333bn MC $525mm MC Sold for

  9. Slide 9: Antibody Therapeutics: Anti-PD-1 Transaction with Servier

    Slide 9: Antibody Therapeutics: Anti-PD-1 Transaction with Servier

    Antibody Therapeutics: Anti-PD-1 Transaction with Servier › On July 6, 2016 Sorrento announced a license and collaboration agreement with Laboratoires Servier for the development, manufacture and commercialization of products using Sorrento’s fully human immuno-oncology anti-PD-1 mAb STI-A1110 o STI

  10. Slide 10: Antibody Therapeutics: Pipeline

    Slide 10: Antibody Therapeutics: Pipeline

    Antibody Therapeutics: Pipeline Lead Candidates in Development Asset Target/Molecule Status STI-A1014 PD-L1 mAb IND filing in 2017 in CN STI-A1110 w/ Servier PD-1 mAb IND-enabling studies IND-enabling studies in KR STI-A1015 w/ Yuhan PD-L1 mAb US clinical trial initiation expected in 1H18 c-MET ADC

  11. Slide 11: LA Cell: iTAb (Intracellular Targeting Antibody) Platform

    Slide 11: LA Cell: iTAb (Intracellular Targeting Antibody) Platform

    LA Cell: iTAb (Intracellular Targeting Antibody) Platform Current mAb/protein drugs target extracellular proteins, either New Class of Drugs for Unmet secreted or membrane bound Medical Needs 2015 sales < 10% potential $169 billion druggable space LA Cell’s proprietary iTAb platform enables the abil

  12. Slide 12: LA Cell: Building the Leading Intracellular Targeting Antibody Company

    Slide 12: LA Cell: Building the Leading Intracellular Targeting Antibody Company

    LA Cell: Building the Leading Intracellular Targeting Antibody (iTAb) Company Program Stage Activities In-Vivo Efficacy Studies STAT3 Lead Optimization Developability Assessment MYC Lead Discovery Functionality Evaluation FOXP3 Lead Discovery Antibody Modification KRAS Lead Discovery Antibody Modifi

  13. Slide 13: Concortis Biotherapeutics (Antibody-Drug Conjugates)

    Slide 13: Concortis Biotherapeutics (Antibody-Drug Conjugates)

    Sorrento Antibody Therapy Business: Concortis Biotherapeutics (Antibody-Drug Conjugates) Next-Generation Antibody-Drug Conjugates › Cytotoxic drugs conjugated to antibodies via chemical linkers › Site-specific conjugation methods to provide homogenous products o K-Lock™ and C-Lock™ › Proprietary tox

  14. Slide 14: Sorrento Biologics (Biosimilars and Biobetters)

    Slide 14: Sorrento Biologics (Biosimilars and Biobetters)

    Sorrento Antibody Therapy Business: Sorrento Biologics (Biosimilars and Biobetters) Pipeline Overview › Exclusive licensing agreement with Mabtech Limited to develop and commercialize biosimilar antibodies › 4 antibodies to date targeting ~$9B global market: Sorrento Global Sales Antibody Generic Ta

  15. Slide 15: Antibody Therapy Business: Key Near-term Milestones

    Slide 15: Antibody Therapy Business: Key Near-term Milestones

    Sorrento Antibody Therapy Business: Key Near-term Milestones Event Timing › Potential LA Cell (iTAb) partnership 2017 › STI-001 (Erbitux biosimilar) FDA discussion on regulatory pathway 2017 › IND filing for c-MET ADC 2017 / 2018 › Initiate PhaseI1 trial for two PD-L1 mAbs 2017 / 2018 › IND filing f

  16. Slide 16: Cell-Based Immunotherapy Business: TNK Therapeutics

    Slide 16: Cell-Based Immunotherapy Business: TNK Therapeutics

    Sorrento Cell-Based Immunotherapy Business: TNK Therapeutics Business Overview Highlights › New treatment modality using genetically modified human immune cells (T › 3 product candidates expected to be in clinical trials in 2017 or NK cells) to attack cancer cells › Promising human proof-of-concept

  17. Slide 17: Anti-CD38 CAR-T Program For Treatment of Multiple Myeloma

    Slide 17: Anti-CD38 CAR-T Program For Treatment of Multiple Myeloma

    Anti-CD38 CAR-T Program For Treatment of Multiple Myeloma (MM) MM Overview: › ACS estimated 30,330 new multiple myeloma cases in 2016 › Malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure Anti-CD38 CAR-T Cells Selectively Lyse CD38 High E

  18. Slide 18: Seprehvir - Leading Next-Generation HSV-1 based Oncolytic Virus Immunotherapy

    Slide 18: Seprehvir - Leading Next-Generation HSV-1 based Oncolytic Virus Immunotherapy

    Seprehvir® - Leading Next-Generation HSV-1 based Oncolytic Virus Immunotherapy  Seprehvir (HSV1716) is a Phase II-ready HSV-1 based immuno-oncolytic therapy with over 100 patients treated to date and no adverse events  Designed with the ability to specifically target and destroy tumor cells while

  19. Slide 19: Seprehvir - Safe in Over 100 patients and Three Delivery Routes

    Slide 19: Seprehvir - Safe in Over 100 patients and Three Delivery Routes

    Seprehvir - Safe in Over 100 patients and Three Delivery Routes By Indication By Delivery Route Systemic 6% Non-CNS Loco-regional 15% 12% MPM HGG 12% 48% Melanoma Intratumoral 5% HNSCC 82% 20%  101 patients treated with Seprehvir in the U.S. and Europe (as of December 2016)  Well tolerated, no tox

  20. Slide 20: Highlights from Phase Ib Trial for CEA CAR-T

    Slide 20: Highlights from Phase Ib Trial for CEA CAR-T

    Highlights from Phase Ib Trial for CEA CAR-T CEA CAR-T CEA CAR-T in Metastatic Liver PET Scans Cancer Patients #4 100% Pre-treatment Post CAR-T ACTIVITY IN HEAVILY PRE-TREATED GROUP (1) #8  Patient #5 alive >130 weeks  Average of 2.5 lines prior chemotherapy 80%  Average size of largest tumor = 8

  21. Slide 21: Key Near-term Milestones for Cell-Based Immunotherapy Business

    Slide 21: Key Near-term Milestones for Cell-Based Immunotherapy Business

    Key Near-term Milestones for Cell-Based Immunotherapy Business Event Timing › Potential JV with Celularity and one or more parties in Cell Therapy 2017 › IND filing for CD38 CAR-T & CAR-NK 2H 2017 › Initiate Phase I CD38 CAR-T & CAR-NK trials for multiple myeloma Late 2017 › Initiate Phase II Sepreh

  22. Slide 22: Scintilla & Scilex Pharmaceuticals: Late-Stage Pain Management Programs

    Slide 22: Scintilla & Scilex Pharmaceuticals: Late-Stage Pain Management Programs

    Scintilla & Scilex Pharmaceuticals: Late-Stage Pain Management Programs RTX SP-102 ZTlido™ (resiniferatoxin) (lidocaine patch 1.8%) • Non-opiate epidural steroid • Non-opioid-based ultrapotent injectable • Anhydrous, single-layer lidocaine Asset Overview TRPV1 agonist neurotoxin injectable patch bas

  23. Slide 23: Pain Management Business: Scilex Pharmaceuticals

    Slide 23: Pain Management Business: Scilex Pharmaceuticals

    Sorrento Pain Management Business: Scilex Pharmaceuticals In November 2016, Sorrento acquired Scilex Pharmaceuticals and its lead product candidate ZTlido › ZTlido is a branded, non-aqueous, topical lidocaine patch for pain associated with post-herpetic neuralgia › Benefits vs. market leader, Lidode

  24. Slide 24: Scilex: ZTlido Regulatory Status

    Slide 24: Scilex: ZTlido Regulatory Status

    Scilex: ZTlido Regulatory Status Submitted NDA based on 505(b)(2) regulatory pathway in 3Q15 › 12-hour adhesion trial (ADH-001) confirmed ≥90% adhesion in 90% subjects (n=54) › Heat and exercise trial (HEX-001) conducted (n=12) › 3 dermal safety trials (totaling 326 patients) conducted to assess pot

  25. Slide 25: Key Near-term Milestones for Pain Management Businesses

    Slide 25: Key Near-term Milestones for Pain Management Businesses

    Key Near-term Milestones for Pain Management Businesses Event Timing › Initiate Phase I/II epidural trial for RTX 1H 2017 › NDA resubmission for ZTlido in US Mid 2017 › MAA submission for ZTlido in EU Mid 2017 › Potential US approval of ZTlido 2H 2017 › Potential EU approval of ZTlido Mid 2018 › Ini

  26. Slide 26: Global Partners: Immuno-Oncology, Cellular Therapy, ADC

    Slide 26: Global Partners: Immuno-Oncology, Cellular Therapy, ADC

    Global Partners: Immuno-Oncology, Cellular Therapy, ADC Partner Asset Type Partner Background Partnership Details • License and collaboration agreement for the development, manufacture and • Servier is the largest non-listed pharmaceutical Laboratoires Servier Immuno-Oncology company in France comme

  27. Slide 27: 2016 Strategic Accomplishments

    Slide 27: 2016 Strategic Accomplishments

    2016 Strategic Accomplishments • Servier PD-1 mAb license validates core G-MAB technology with potential development and Core Technology Validation commercial milestones totaling about $1 billion • Pain management franchise built out and moving forward with internal investments and acquisitions (SCI

  28. Slide 28: Contact Us

    Slide 28: Contact Us

    Contact Us (858) 210-3700 9380 Judicial Drive, San Diego, CA 92121 [email protected] © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 28

Source: company website

More decks from Sorrento Therapeutics, Inc.

All 41 Sorrento Therapeutics decks